ELIZABETH VALLEJO: Open Payments
NPI 1679896856 · BROWNWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$706 in 35 payments from 14 companies in 2025. Trend: 2023 $719 · 2024 $427 · 2025 $706
Food & beverage: $706
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $144 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $97 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $94 |
| ABBVIE INC. | 4 | $85 |
| Novo Nordisk Inc | 5 | $77 |
| Dexcom, Inc. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 4 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: Epclusa, PANHEMATIN, JARDIANCE, VRAYLAR, Dexcom G6 Transmitter, FARXIGA, QULIPTA, Ozempic.
Industry payments across TX — which companies pay providers there.
